Fadia T Shaya1, Anna Gu, Xia Yan. 1. Dr. Shaya is Associate Professor in the Department of Pharmaceutical Health Services Research at the University of Maryland's School of Pharmacy in Baltimore, Maryland. At the time of this writing, Dr. Gu was a Graduate Research Assistant and doctoral student at the university. She is currently an Associate Consultant for Analysis Group, Inc., in Boston, Massachusetts. Ms. Yan is a doctoral student in the Department of Pharmaceutical Health Services Research at the University of Maryland.
Abstract
OBJECTIVE: We conducted a study to assess the effect of persistence with therapy in the use of statins, beta blockers, or calcium-channel blockers on the recurrence of myocardial infarction or death in a Medicaid high-risk, largely female, African-American population. STUDY DESIGN: This was a prospective nonconcurrent cohort, longitudinal data analysis of medical and pharmacy claims of acute myocardial infarction (AMI) patients from Medicaid managed care organizations between January 1, 2002, and December 31, 2004. METHODS: Cox proportional hazards models were used to predict the likelihood of a re-infarction as a function of persistence with the use of the initial medication after an AMI. We made adjustments for age, race, sex, heart disease, and other comorbidities as well as the pharmacotherapies prescribed. RESULTS: Among 515 AMI patients (58.1% female, 46% African-American), the most prevalent comorbidities were hypertension (90.9%) and heart disease (80.6%). Most initial AMIs were non-transmural. Discontinuation of statins, beta blockers, or calcium-channel blockers after an AMI increased the likelihood of a re-infarction (hazard ratio, 1.66; 95% confidence interval, 1.03-2.69). Concurrent heart disease, hyperlipidemia, or renal disease significantly increased the probability of having a re-infarction, but age, race, and sex did not significantly predict the likelihood of re-infarction or death. CONCLUSION: Persistence of therapy in the use of the initial AMI-preventive medication after an AMI was effective in avoiding re-infarction or death. Heart disease, renal disease, and hyperlipidemia increased the likelihood of an adverse outcome.
OBJECTIVE: We conducted a study to assess the effect of persistence with therapy in the use of statins, beta blockers, or calcium-channel blockers on the recurrence of myocardial infarction or death in a Medicaid high-risk, largely female, African-American population. STUDY DESIGN: This was a prospective nonconcurrent cohort, longitudinal data analysis of medical and pharmacy claims of acute myocardial infarction (AMI) patients from Medicaid managed care organizations between January 1, 2002, and December 31, 2004. METHODS: Cox proportional hazards models were used to predict the likelihood of a re-infarction as a function of persistence with the use of the initial medication after an AMI. We made adjustments for age, race, sex, heart disease, and other comorbidities as well as the pharmacotherapies prescribed. RESULTS: Among 515 AMI patients (58.1% female, 46% African-American), the most prevalent comorbidities were hypertension (90.9%) and heart disease (80.6%). Most initial AMIs were non-transmural. Discontinuation of statins, beta blockers, or calcium-channel blockers after an AMI increased the likelihood of a re-infarction (hazard ratio, 1.66; 95% confidence interval, 1.03-2.69). Concurrent heart disease, hyperlipidemia, or renal disease significantly increased the probability of having a re-infarction, but age, race, and sex did not significantly predict the likelihood of re-infarction or death. CONCLUSION: Persistence of therapy in the use of the initial AMI-preventive medication after an AMI was effective in avoiding re-infarction or death. Heart disease, renal disease, and hyperlipidemia increased the likelihood of an adverse outcome.
Authors: J Stamler; R Stamler; J D Neaton; D Wentworth; M L Daviglus; D Garside; A R Dyer; K Liu; P Greenland Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: Fadia T Shaya; Antoine C El Khoury; C Daniel Mullins; Dongyi Du; Richard Skolasky; Hugh Fatodu; Howard Garber; Matthew R Weir Journal: Am J Manag Care Date: 2006-06 Impact factor: 2.229
Authors: Giuseppe De Luca; Nicolette Ernst; Arnoud W J van 't Hof; Jan Paul Ottervanger; Jan C A Hoorntje; A T Marcel Gosselink; Jan-Henk E Dambrink; Menko-Jan de Boer; Harry Suryapranata Journal: Am Heart J Date: 2006-06 Impact factor: 4.749
Authors: Nagesh S Anavekar; John J V McMurray; Eric J Velazquez; Scott D Solomon; Lars Kober; Jean-Lucien Rouleau; Harvey D White; Rolf Nordlander; Aldo Maggioni; Kenneth Dickstein; Steven Zelenkofske; Jeffrey D Leimberger; Robert M Califf; Marc A Pfeffer Journal: N Engl J Med Date: 2004-09-23 Impact factor: 91.245
Authors: Frans Van de Werf; Diego Ardissino; Amadeo Betriu; Dennis V Cokkinos; Erling Falk; Keith A A Fox; Desmond Julian; Maria Lengyel; Franz-Josef Neumann; Witold Ruzyllo; Christian Thygesen; S Richard Underwood; Alec Vahanian; Freek W A Verheugt; William Wijns Journal: Eur Heart J Date: 2003-01 Impact factor: 29.983
Authors: Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs Journal: Circulation Date: 2004-08-03 Impact factor: 29.690
Authors: Umesh N Khot; Monica B Khot; Christopher T Bajzer; Shelly K Sapp; E Magnus Ohman; Sorin J Brener; Stephen G Ellis; A Michael Lincoff; Eric J Topol Journal: JAMA Date: 2003-08-20 Impact factor: 56.272